Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 11:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 3,045 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Long Term Clear all
Terminated No phase listed Observational

Use of AEEG as Predictor of Long-term Motor Outcome in Neonates With Congenital Heart Disease

NCT01291797
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
1 Day to 2 Months
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 15, 2026, 11:56 PM EDT
Enrolling by invitation No phase listed Observational

A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301

NCT06363760
View directory record Official record
Conditions
Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia, Hemoglobinopathies
Interventions
Safety and efficacy assessments
Other
Lead sponsor
Editas Medicine, Inc.
Industry
Eligibility
12 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2040
U.S. locations
16
States / cities
Oakland, California • Aurora, Colorado • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 15, 2026, 11:56 PM EDT
Active, not recruiting Phase 2 Interventional

Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

NCT04954859
View directory record Official record
Conditions
Hepatitis B
Interventions
Bepirovirsen, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
5
States / cities
Sacramento, California • San Jose, California • Colorado Springs, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 15, 2026, 11:56 PM EDT
Active, not recruiting No phase listed Observational

Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes

NCT05506423
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
CycloPen Cyclodialysis System
Device
Lead sponsor
Iantrek, Inc.
Industry
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Newport Beach, California • Cape Coral, Florida • DeLand, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 15, 2026, 11:56 PM EDT
Completed Not applicable Interventional

Study of Default Options in Advance Directives

NCT01817686
View directory record Official record
Conditions
COPD, Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy, Idiopathic Pulmonary Fibrosis, Other Interstitial Lung Disease Without Curative Therapy, Congestive Heart Failure, NYHA Class IV or NYHA Class III Plus 1 Hospitalization in the Past Year, Malignancy, Any Stage 3B or 4 Solid Tumor
Interventions
Comfort Default AD forms, Life Extension Default AD forms, Standard Default AD forms
Other
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Oct 15, 2026, 11:56 PM EDT
Active, not recruiting No phase listed Observational

Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy

NCT05506254
View directory record Official record
Conditions
Methylmalonic Acidemia
Interventions
hLB-001
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
4
States / cities
Atlanta, Georgia • Pittsburgh, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 15, 2026, 11:56 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

NCT00631917
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Ramipril, Placebo to Ramipril, Placebo to Aliskiren
Drug · Other
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Oct 15, 2026, 11:56 PM EDT
Completed No phase listed Observational

Long-Term Effects of HAART in Youth With Stronger Immune Systems Versus Youth With Weaker Immune Systems

NCT00001097
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 22 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
43
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2010 · Synced Oct 15, 2026, 11:56 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

NCT05443724
View directory record Official record
Conditions
Schizophrenia
Interventions
Emraclidine 30 mg
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
62
States / cities
Phoenix, Arizona • Bryant, Arkansas • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 15, 2026, 11:56 PM EDT
Completed No phase listed Observational

Long-Term Follow-Up of Patients Enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS)

NCT00001612
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 15, 2026, 11:56 PM EDT
Completed Not applicable Interventional

Disseminating Effective Habits for Long-Term Weight Loss

NCT00709501
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Disseminating Effective Habits for Long-term Weight Loss, Achieve Together website
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
21 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Oct 15, 2026, 11:56 PM EDT
Completed Not applicable Interventional Results available

Long Term Outcomes of Lumbar Epidural Steroid Injections for Spinal Stenosis

NCT02260401
View directory record Official record
Conditions
Lumbar Spinal Stenosis
Interventions
Individualized report
Other
Lead sponsor
University of Washington
Other
Eligibility
50 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Oct 15, 2026, 11:56 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

NCT02873208
View directory record Official record
Conditions
Schizophrenia
Interventions
ALKS 3831
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
43
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 15, 2026, 11:56 PM EDT
Terminated No phase listed Observational

Sample Collection From Melanoma Patients

NCT00507325
View directory record Official record
Conditions
Melanoma
Interventions
Blood Sample, Tumor Sample
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 15, 2026, 11:56 PM EDT
Completed Phase 3 Interventional Results available

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

NCT05142774
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tapinarof cream, 1%
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
2 Years and older
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
102
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 15, 2026, 11:56 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

NCT07516132
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
OTX-TKI
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
50 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
8
States / cities
Bakersfield, California • Santa Barbara, California • Waterford, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 15, 2026, 11:56 PM EDT
Completed Not applicable Interventional

Promoting Positive Care Interactions (PPCI) in Assisted Living

NCT05618834
View directory record Official record
Conditions
Alzheimer Disease and Related Dementias
Interventions
Promoting Positive Care Interactions (PPCI), PPCI-Staff Education Only (EO)
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
65 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 15, 2026, 11:56 PM EDT
Enrolling by invitation No phase listed Observational

Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies

NCT05041309
View directory record Official record
Conditions
Solid and Hematological Malignancies, Autoimmune Diseases
Interventions
Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, Anitocabtagene autleucel, KITE-753, KITE-197, KITE-363, INT2104, KITE-512, SPRX001, SPRX002, ARC-T Cells
Biological
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2040
U.S. locations
49
States / cities
Gilbert, Arizona • Duarte, California • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 15, 2026, 11:56 PM EDT
Terminated Phase 3 Interventional Results available

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

NCT00858364
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Anemia, Cancer, Lung Cancer
Interventions
Darbepoetin alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
2,549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
277
States / cities
Anniston, Alabama • Birmingham, Alabama • Anchorage, Alaska + 243 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 15, 2026, 11:56 PM EDT
Completed Phase 3 Interventional Results available

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

NCT03399604
View directory record Official record
Conditions
Primary Pulmonary Hypertension
Interventions
LIQ861 Inhaled Treprostinil
Drug
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
38
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 15, 2026, 11:56 PM EDT
Terminated Phase 2 Interventional

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

NCT02616055
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
tesevatinib
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years to 62 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Los Angeles, California • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 15, 2026, 11:56 PM EDT
Suspended Phase 2Phase 3 Interventional

Rollover Extension Clinical Trial To Evaluate The Long-Term Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With CKD IV Completing The US-APR2020-01 Study

NCT05407389
View directory record Official record
Conditions
Chronic Kidney Disease stage4
Interventions
KT-301 (formerly US-APR2020)
Drug
Lead sponsor
Kibow Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Silver Spring, Maryland • Saginaw, Michigan • Orangeburg, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 15, 2026, 11:56 PM EDT
Recruiting No phase listed Observational

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

NCT04561518
View directory record Official record
Conditions
Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis
Interventions
Not listed
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2033
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 11:56 PM EDT
Completed Not applicable Interventional

Surgery Plus Celiac Nerve Block for Long-term Pancreatic Cancer Pain Control

NCT02002806
View directory record Official record
Conditions
Pancreas Cancer, Biliary Tract Cancer
Interventions
Alcohol Injection, Placebo Injection
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 16, 2019 · Synced Oct 15, 2026, 11:56 PM EDT